Swiss pharmaceutical group, Helsinn, has opened an office in Shanghai, China, as part of the group’s commitment to the region — Helsinn Pharmaceuticals (Beijing).
Shanghai
The establishment of this office will enable Helsinn to expand its presence in China and seek pan-China collaborations with partners in anticipation of future product launches. Currently, the company has several products under registration with the Chinese Food and Drug Administration (CFDA), which it anticipates will be approved next year.
“Helsinn has been developing a presence in China over the past five years and we have developed valuable experience, learnings and network. With the opening of our Shanghai office we will now be more visible and have the opportunity to capitalise on the groundwork we have already put in,” explained Riccardo Braglia, Helsinn Group vice chairman and CEO. “China is a large, diverse and dynamic market and we’re delighted to have a permanent presence here as we expand our global footprint and seek to build out new avenues to help more people with cancer around the world.”